SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/168814"
 

Search: onr:"swepub:oai:gup.ub.gu.se/168814" > Treatment of Alzhei...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Treatment of Alzheimer's disease with clioquinol.

Regland, Björn, 1947 (author)
Gothenburg University,Göteborgs universitet,Institutionen för klinisk neurovetenskap,Institute of Clinical Neurosciences
Lehmann, W (author)
Abedini, I (author)
show more...
Blennow, Kaj, 1958 (author)
Gothenburg University,Göteborgs universitet,Institutionen för klinisk neurovetenskap,Institute of Clinical Neurosciences
Jonsson, Michael, 1955 (author)
Gothenburg University,Göteborgs universitet,Institutionen för klinisk neurovetenskap,Institute of Clinical Neurosciences
Karlsson, Ingvar, 1941 (author)
Gothenburg University,Göteborgs universitet,Institutionen för klinisk neurovetenskap,Institute of Clinical Neurosciences
Sjögren, Magnus (author)
Gothenburg University,Göteborgs universitet,Institutionen för klinisk neurovetenskap,Institute of Clinical Neurosciences
Wallin, Anders, 1950 (author)
Gothenburg University,Göteborgs universitet,Institutionen för klinisk neurovetenskap,Institute of Clinical Neurosciences
Xilinas, M (author)
Gottfries, Carl-Gerhard, 1928 (author)
Gothenburg University,Göteborgs universitet,Institutionen för klinisk neurovetenskap,Institute of Clinical Neurosciences
show less...
 (creator_code:org_t)
2001
2001
English.
In: Dementia and geriatric cognitive disorders. - 1420-8008. ; 12:6, s. 408-14
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • As heavy metal ions may be implicated in the formation of senile plaques in Alzheimer-afflicted brains, treatment with clioquinol was tested in 20 patients with Alzheimer's disease. Clioquinol is a chelator that crosses the blood-brain barrier and has greater affinity for zinc and copper ions than for calcium and magnesium ions. Treatment was given for 21 days at doses of 20 mg/day to 10 patients and 80 mg/day to another 10 patients. The study was blind to the dosages but included no controls. Cerebrospinal fluid (CSF) investigations revealed a significant increase at day 7 and a decrease at day 21 in Tau protein and growth-associated protein (GAP43). These proteins are increased in Alzheimer's disease and considered as rather stable markers. The initial increase may indicate a temporary cytotoxicity to the brain and/or an increased release into the CSF from stores in the tissue, possibly from senile plaques where the proteins are accumulated. The levels of CSF-Tau protein correlated positively and significantly with the serum levels of copper and also with the serum copper/zinc ratio. Clinical ratings showed slight improvement after 3 weeks treatment with clioquinol in this open study.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Keyword

Aged
Aged
80 and over
Alzheimer Disease
blood
cerebrospinal fluid
drug therapy
Chelating Agents
administration & dosage
adverse effects
therapeutic use
Chelation Therapy
methods
Clioquinol
administration & dosage
adverse effects
therapeutic use
Copper
blood
Dose-Response Relationship
Drug
Female
GAP-43 Protein
cerebrospinal fluid
drug effects
Humans
Male
Middle Aged
Treatment Outcome
Zinc
blood
tau Proteins
cerebrospinal fluid
drug effects

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view